Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2030 earnings at $0.01 EPS.
Separately, Weiss Ratings raised shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 10th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oncolytics Biotech has an average rating of “Hold” and an average target price of $5.00.
View Our Latest Analysis on ONCY
Oncolytics Biotech Stock Performance
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Analysts predict that Oncolytics Biotech will post -0.29 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oncolytics Biotech
A number of hedge funds have recently modified their holdings of the business. Vantage Point Financial LLC bought a new position in shares of Oncolytics Biotech during the 2nd quarter valued at about $28,000. Fifth Third Bancorp grew its position in shares of Oncolytics Biotech by 87.9% in the 3rd quarter. Fifth Third Bancorp now owns 85,526 shares of the company’s stock valued at $57,000 after purchasing an additional 40,000 shares during the period. Susquehanna International Group LLP grew its position in shares of Oncolytics Biotech by 224.6% in the 2nd quarter. Susquehanna International Group LLP now owns 134,129 shares of the company’s stock valued at $127,000 after purchasing an additional 92,806 shares during the period. Connective Capital Management LLC bought a new stake in Oncolytics Biotech during the 2nd quarter worth approximately $176,000. Finally, International Assets Investment Management LLC increased its stake in Oncolytics Biotech by 129.6% during the 3rd quarter. International Assets Investment Management LLC now owns 462,008 shares of the company’s stock worth $310,000 after purchasing an additional 260,748 shares in the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.
Oncolytics Biotech Company Profile
Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer. The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment. Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions.
Recommended Stories
- Five stocks we like better than Oncolytics Biotech
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
